DR4 Cancer Research Results

DR4, Death Receptor 4: Click to Expand ⟱
Source:
Type: protein
DR4 (Death Receptor 4, also known as TRAIL receptor 1 or TNFRSF10A).
DR4 is one of the main receptors for TRAIL (TNF-related apoptosis-inducing ligand). • Upon TRAIL binding, DR4 can trigger the extrinsic apoptotic pathway, leading to caspase activation and programmed cell death.

Lower receptor levels often correlate with therapy resistance and aggressive tumor phenotypes, while appropriate or higher levels may enhance susceptibility to apoptosis-based therapies.
Scientific Papers found: Click to Expand⟱
1521- Ba,    Baicalein induces apoptosis via ROS-dependent activation of caspases in human bladder cancer 5637 cells
- in-vitro, Bladder, 5637
TumCG↓, Apoptosis↑, IAP1↓, IAP2↓, Casp3↑, Casp9↑, BAX↑, Bcl-2↓, MMP↓, Casp8↑, BID↑, ROS?, eff↓, DR4↑, DR5↑, FasL↑, TRAIL↑,
2767- Bos,    The potential role of boswellic acids in cancer prevention and treatment
- Review, Var, NA
*Inflam↓, AntiCan↑, *MAPK↑, *Ca+2↝, p‑ERK↓, TumCI↓, cycD1/CCND1↓, cycE/CCNE↓, CDK2↓, CDK4↓, p‑RB1↓, *NF-kB↓, *TNF-α↓, NF-kB↓, IKKα↓, MCP1↓, IL1α↓, MIP2↓, VEGF↓, Tf↓, COX2↓, MMP9↓, CXCR4↓, VEGF↓, eff↑, PPARα↓, lipid-P?, STAT3↓, TOP1↓, TOP2↑, 5HT↓, p‑PDGFR-BB↓, PDGF↓, AR↓, DR5↑, angioG↓, DR4↑, Casp3↑, Casp8↑, cl‑PARP↑, eff↑, chemoPv↑, Wnt↓, β-catenin/ZEB1↓, ascitic↓, Let-7↑, miR-200b↑, eff↑, MMP1↓, MMP2↓, eff↑, BioAv↓, BioAv↑, Half-Life↓, toxicity↓, Dose↑, BioAv↑, ChemoSen↑,
1448- Bos,    A triterpenediol from Boswellia serrata induces apoptosis through both the intrinsic and extrinsic apoptotic pathways in human leukemia HL-60 cells
- in-vitro, AML, HL-60
TumCP↓, Apoptosis↑, ROS↑, NO↑, cl‑Bcl-2↑, BAX↑, MMP↓, Cyt‑c↑, AIF↑, Diablo↑, survivin↓, ICAD↓, Casp↑, cl‑PARP↑, DR4↑, TNFR 1↑,
1621- EA,    The multifaceted mechanisms of ellagic acid in the treatment of tumors: State-of-the-art
- Review, Var, NA
AntiCan↑, Apoptosis↑, TumCP↓, TumMeta↓, TumCI↓, TumAuto↑, VEGFR2↓, MAPK↓, PI3K↓, Akt↓, PD-1↓, NOTCH↓, PCNA↓, Ki-67↓, cycD1/CCND1↓, CDK2↑, CDK6↓, Bcl-2↓, cl‑PARP↑, BAX↑, Casp3↑, DR4↑, DR5↑, Snail↓, MMP2↓, MMP9↓, TGF-β↑, PKCδ↓, β-catenin/ZEB1↓, SIRT1↓, HO-1↓, ROS↑, CHOP↑, Cyt‑c↑, MMP↓, OCR↓, AMPK↑, Hif1a↓, NF-kB↓, E-cadherin↑, Vim↓, EMT↓, LC3II↑, CIP2A↓, GLUT1↓, PDH↝, MAD↓, LDH↓, GSTs↑, NOTCH↓, survivin↓, XIAP↓, ER Stress↑, ChemoSideEff↓, ChemoSen↑,
6385- Eug,    Anticancer potential of eugenol in hepatocellular carcinoma through modulation of oxidative stress, inflammation, apoptosis, and proliferation mechanisms
- in-vivo, HCC, HepG2
tumCV↓, TumCMig↓, *ALAT↓, *AST↓, *ALP↓, *Bil↓, *CEA↓, *lipid-P↓, *TNF-α↓, *IL1β↓, NF-kB↓, CXCR3↓, HRAS↓, KRAS↓, Ki-67↓, *GSH↑, *GPx↑, *SOD↑, *NRF2↑, P53↑, BAX↑, DR4↑, DR5↑,
2828- FIS,    Fisetin, a Potent Anticancer Flavonol Exhibiting Cytotoxic Activity against Neoplastic Malignant Cells and Cancerous Conditions: A Scoping, Comprehensive Review
- Review, Var, NA
*neuroP↑, *antiOx↑, *Inflam↓, RenoP↑, COX2↓, Wnt↓, EGFR↓, NF-kB↓, Casp3↑, Ca+2↑, Casp8↑, TumCCA↑, CDK1↓, PI3K↓, Akt↓, mTOR↓, MAPK↓, *P53↓, *P21↓, *p16↓, mTORC1↓, mTORC2↓, P53↑, P21↑, cycD1/CCND1↓, cycA1/CCNA1↓, CDK2↓, CDK4↓, BAX↑, Bcl-2↓, PCNA↓, HER2/EBBR2↓, Cyt‑c↑, MMP↓, cl‑Casp9↑, MMP2↓, MMP9↓, cl‑PARP↑, uPA↓, DR4↑, DR5↑, ROS↓, AIF↑, CDC25↓, Dose↑, CHOP↑, ROS↑, cMyc↓, cardioP↑,
6492- Nimb,    Review on Molecular and Chemopreventive Potential of Nimbolide in Cancer
- Review, NA, NA
Apoptosis↑, TumCCA↑, TumCP↓, TumCI↓, angioG↓, TumMeta↓, PTEN↑, NF-kB↓, Wnt↓, β-catenin/ZEB1↓, IKKα↓, CXCR2↓, CXCR4↓, Bcl-2↓, COX2↓, MMP9↓, VEGF↓, TIMP2↑, chemoPv↑, ROS↑, DR4↑, P53↑, BAX↑, Casp3↑, Casp8↑, Casp9↑, cl‑PARP↑, Mcl-1↓, XIAP↓, survivin↓, FasL↑, FADD↑, EGFR↓, MMPs↓,
6487- Nimb,    Anticancer properties of nimbolide and pharmacokinetic considerations to accelerate its development
- Review, Var, NA
TumCP↓, Apoptosis↓, TumMeta↑, angioG↓, *antiOx↑, *eff↑, Apoptosis↑, MOMP↑, CDK1↓, TumCCA↑, MAPK↓, JAK2↓, STAT3↓, PI3K↓, Akt↓, TumCP↓, *NRF2↑, NF-kB↓, GSK‐3β↑, Wnt↓, β-catenin/ZEB1↓, chemoPv↑, Bcl-xL↓, Bcl-2↓, survivin↓, Cyt‑c↑, BAX↑, BID↑, cl‑Casp↑, P53↑, DR5↑, DR4↑, ROS↑, lipid-P↑, MDA↑, MMP2↓, MMP9↓, uPA↓, ICAM-1↓, CXCR4↓, CXCR2↓, angioG↓, BBB↑,
4957- PEITC,    Phenethyl Isothiocyanate (PEITC) from Cruciferous Vegetables Targets Human Cancer Stem-Like Cells
- vitro+vivo, Cerv, HeLa
CSCs↓, ALDH↓, CD44↓, CD24↓, cl‑PARP↑, DR4↑, DR5↑,
4960- PEITC,    Phenethyl isothiocyanate upregulates death receptors 4 and 5 and inhibits proliferation in human cancer stem-like cells
- in-vivo, Cerv, HeLa
CD44↓, CD24↓, CSCs↓, cl‑PARP↑, DR4↑, DR5↑, TumCP↓,
4922- PEITC,    Phenethyl Isothiocyanate: A comprehensive review of anti-cancer mechanisms
- Review, Var, NA
Risk↓, AntiCan↑, TumCP↓, TumMeta↓, ChemoSen↑, *BioAv↑, *other↝, *Dose↝, Dose↓, *BioAv↑, *Dose↝, *Half-Life↝, *toxicity↝, GSH↓, ROS↑, CYP1A1↑, CYP1A2↑, P450↓, CYP2E1↑, CYP3A4↓, CYP2A3/CYP2A6↓, *ROS↓, *GPx1↑, *SOD1↑, *SOD2↑, Akt↓, EGFR↓, HER2/EBBR2↓, P53↑, Telomerase↓, selectivity↑, MMP↓, Cyt‑c↑, Apoptosis↑, DR4↑, Fas↑, XIAP↓, survivin↓, TumAuto↑, Hif1a↓, angioG↓, MMPs↓, ERK↓, NF-kB↓, EMT↓, TumCI↓, TumCMig↓, Glycolysis↓, ATP↓, selectivity↑, *antiOx↑, Dose↝, other↝, OCR↓, GSH↓, ITGB1↓, ITGB6↓, ChemoSen↑,
4918- PEITC,    Nutritional Sources and Anticancer Potential of Phenethyl Isothiocyanate: Molecular Mechanisms and Therapeutic Insights
- Review, Var, NA
Apoptosis↑, TumCP↓, angioG↓, TumMeta↓, NF-kB↓, Akt↓, MAPK↓, *BioAv↓, ROS↑, lipid-P↑, AIF↑, Cyt‑c↑, DR4↑, DR5↑, TumCCA↑, JAK↓, STAT3↓, MMP2↓, MMP9↓, PKCδ↓, Hif1a↓, JNK↓, Mcl-1↓, COX2↓, MMP↓, Casp3↑, ChemoSen↑, *BioAv↓, Half-Life↓,
5159- PLB,    Plumbagin treatment leads to apoptosis in human K562 leukemia cells through increased ROS and elevated TRAIL receptor expression
- in-vitro, AML, K562
tumCV↓, Apoptosis↑, ROS↑, eff↓, DR4↑, DR5↑, TRAIL↑,
64- QC,    Quercetin enhances TRAIL-mediated apoptosis in colon cancer cells by inducing the accumulation of death receptors in lipid rafts
- in-vitro, Colon, HT-29 - in-vitro, Colon, SW-620 - in-vitro, Colon, Caco-2
Cyt‑c↑, BAX↑, Casp3↑, DR4↑, DR5↑,
3098- RES,    Regulation of Cell Signaling Pathways and miRNAs by Resveratrol in Different Cancers
- Review, Var, NA
NOTCH2↓, Wnt↓, β-catenin/ZEB1↓, p‑SMAD2↓, p‑SMAD3↓, PTCH1↓, Smo↓, Gli1↓, E-cadherin↑, NOTCH⇅, TAC?, NKG2D↑, DR4↑, survivin↓, DR5↑, BAX↑, p27↑, cycD1/CCND1↓, Bcl-2↓, STAT3↓, STAT5↓, JAK↓, DNAdam↑, γH2AX↑,
3061- RES,    The Anticancer Effects of Resveratrol: Modulation of Transcription Factors
- Review, Var, NA
AhR↓, NRF2↑, *NQO1↑, *HO-1↑, *GSH↑, P53↑, Cyt‑c↑, Diablo↑, Bcl-2↓, Bcl-xL↓, survivin↓, XIAP↓, FOXO↑, p‑PI3K↓, p‑Akt↓, BIM↑, DR4↑, DR5↑, p27↑, cycD1/CCND1↓, SIRT1↑, NF-kB↓, ATF3↑,
1469- SFN,    Sulforaphane enhances the therapeutic potential of TRAIL in prostate cancer orthotopic model through regulation of apoptosis, metastasis, and angiogenesis
- in-vitro, Pca, PC3 - in-vitro, Pca, LNCaP - in-vivo, Pca, NA
eff↑, ROS↑, MMP↓, Casp3↑, Casp9↑, DR4↑, DR5↑, BAX↑, Bak↑, BIM↑, NOXA↑, Bcl-2↓, Bcl-xL↓, Mcl-1↓, eff↓, TumCG↓, TumCP↓, eff↑, NF-kB↓, PI3K↓, Akt↓, MEK↓, ERK↓, angioG↓, FOXO3↑,
1928- TQ,    Thymoquinone Crosstalks with DR5 to Sensitize TRAIL Resistance and Stimulate ROS-Mediated Cancer Apoptosis
- in-vitro, BC, MCF7 - in-vitro, BC, MDA-MB-231
TumCP↓, DR4↑, DR5↑, Casp8↑, FADD↑, Bcl-2↓, ROS↑, NO↑, MDA↑,

Showing Research Papers: 1 to 18 of 18

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 18

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned(tgid=0) ⓘ

CXCR3↓, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

ATF3↑, 1,   CYP1A1↑, 1,   CYP2E1↑, 1,   GSH↓, 2,   GSTs↑, 1,   HO-1↓, 1,   lipid-P?, 1,   lipid-P↑, 2,   MAD↓, 1,   MDA↑, 2,   NRF2↑, 1,   ROS?, 1,   ROS↓, 1,   ROS↑, 10,   TAC?, 1,  

Metal & Cofactor Biology(tgid=2) ⓘ

Tf↓, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

AIF↑, 3,   ATP↓, 1,   CDC25↓, 1,   MEK↓, 1,   MMP↓, 7,   OCR↓, 2,   XIAP↓, 4,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

AMPK↑, 1,   cMyc↓, 1,   CYP3A4↓, 1,   Glycolysis↓, 1,   LDH↓, 1,   PDH↝, 1,   PPARα↓, 1,   SIRT1↓, 1,   SIRT1↑, 1,  

Cell Death(tgid=5) ⓘ

AhR↓, 1,   Akt↓, 6,   p‑Akt↓, 1,   Apoptosis↓, 1,   Apoptosis↑, 8,   Bak↑, 1,   BAX↑, 10,   Bcl-2↓, 9,   cl‑Bcl-2↑, 1,   Bcl-xL↓, 3,   BID↑, 2,   BIM↑, 2,   Casp↑, 1,   cl‑Casp↑, 1,   Casp3↑, 8,   Casp8↑, 5,   Casp9↑, 3,   cl‑Casp9↑, 1,   Cyt‑c↑, 8,   Diablo↑, 2,   DR4↑, 18,   DR5↑, 15,   FADD↑, 2,   Fas↑, 1,   FasL↑, 2,   IAP1↓, 1,   IAP2↓, 1,   ICAD↓, 1,   JNK↓, 1,   MAPK↓, 4,   Mcl-1↓, 3,   MOMP↑, 1,   NOXA↑, 1,   p27↑, 2,   survivin↓, 7,   Telomerase↓, 1,   TNFR 1↑, 1,   TRAIL↑, 2,  

Kinase & Signal Transduction(tgid=6) ⓘ

HER2/EBBR2↓, 2,  

Transcription & Epigenetics(tgid=7) ⓘ

other↝, 1,   tumCV↓, 2,  

Protein Folding & ER Stress(tgid=8) ⓘ

CHOP↑, 2,   ER Stress↑, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

LC3II↑, 1,   TumAuto↑, 2,  

DNA Damage & Repair(tgid=10) ⓘ

DNAdam↑, 1,   P53↑, 6,   cl‑PARP↑, 7,   PCNA↓, 2,   γH2AX↑, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK1↓, 2,   CDK2↓, 2,   CDK2↑, 1,   CDK4↓, 2,   cycA1/CCNA1↓, 1,   cycD1/CCND1↓, 5,   cycE/CCNE↓, 1,   P21↑, 1,   p‑RB1↓, 1,   TumCCA↑, 4,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

ALDH↓, 1,   CD24↓, 2,   CD44↓, 2,   CIP2A↓, 1,   CSCs↓, 2,   EMT↓, 2,   ERK↓, 2,   p‑ERK↓, 1,   FOXO↑, 1,   FOXO3↑, 1,   Gli1↓, 1,   GSK‐3β↑, 1,   HRAS↓, 1,   Let-7↑, 1,   mTOR↓, 1,   mTORC1↓, 1,   mTORC2↓, 1,   NOTCH↓, 2,   NOTCH⇅, 1,   NOTCH2↓, 1,   PI3K↓, 4,   p‑PI3K↓, 1,   PTCH1↓, 1,   PTEN↑, 1,   Smo↓, 1,   STAT3↓, 4,   STAT5↓, 1,   TOP1↓, 1,   TOP2↑, 1,   TumCG↓, 2,   Wnt↓, 5,  

Migration(tgid=13) ⓘ

Ca+2↑, 1,   E-cadherin↑, 2,   ITGB1↓, 1,   ITGB6↓, 1,   Ki-67↓, 2,   KRAS↓, 1,   miR-200b↑, 1,   MMP1↓, 1,   MMP2↓, 5,   MMP9↓, 6,   MMPs↓, 2,   PDGF↓, 1,   PKCδ↓, 2,   p‑SMAD2↓, 1,   p‑SMAD3↓, 1,   Snail↓, 1,   TGF-β↑, 1,   TIMP2↑, 1,   TumCI↓, 4,   TumCMig↓, 2,   TumCP↓, 10,   TumMeta↓, 4,   TumMeta↑, 1,   uPA↓, 2,   Vim↓, 1,   β-catenin/ZEB1↓, 5,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 7,   EGFR↓, 3,   Hif1a↓, 3,   NO↑, 2,   p‑PDGFR-BB↓, 1,   VEGF↓, 3,   VEGFR2↓, 1,  

Barriers & Transport(tgid=15) ⓘ

BBB↑, 1,   GLUT1↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2↓, 4,   CXCR2↓, 2,   CXCR4↓, 3,   ICAM-1↓, 1,   IKKα↓, 2,   IL1α↓, 1,   JAK↓, 2,   JAK2↓, 1,   MCP1↓, 1,   MIP2↓, 1,   NF-kB↓, 10,   PD-1↓, 1,  

Synaptic & Neurotransmission(tgid=18) ⓘ

5HT↓, 1,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

AR↓, 1,   CDK6↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 1,   BioAv↑, 2,   ChemoSen↑, 5,   CYP1A2↑, 1,   CYP2A3/CYP2A6↓, 1,   Dose↓, 1,   Dose↑, 2,   Dose↝, 1,   eff↓, 3,   eff↑, 6,   Half-Life↓, 2,   P450↓, 1,   selectivity↑, 2,  

Clinical Biomarkers(tgid=22) ⓘ

AR↓, 1,   ascitic↓, 1,   EGFR↓, 3,   HER2/EBBR2↓, 2,   Ki-67↓, 2,   KRAS↓, 1,   LDH↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 3,   cardioP↑, 1,   chemoPv↑, 3,   ChemoSideEff↓, 1,   NKG2D↑, 1,   RenoP↑, 1,   Risk↓, 1,   toxicity↓, 1,  
Total Targets: 202

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 3,   Bil↓, 1,   GPx↑, 1,   GPx1↑, 1,   GSH↑, 2,   HO-1↑, 1,   lipid-P↓, 1,   NQO1↑, 1,   NRF2↑, 2,   ROS↓, 1,   SOD↑, 1,   SOD1↑, 1,   SOD2↑, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

ALAT↓, 1,  

Cell Death(tgid=5) ⓘ

MAPK↑, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

other↝, 1,  

DNA Damage & Repair(tgid=10) ⓘ

p16↓, 1,   P53↓, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

P21↓, 1,  

Migration(tgid=13) ⓘ

Ca+2↝, 1,   CEA↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

IL1β↓, 1,   Inflam↓, 2,   NF-kB↓, 1,   TNF-α↓, 2,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 2,   BioAv↑, 2,   Dose↝, 2,   eff↑, 1,   Half-Life↝, 1,  

Clinical Biomarkers(tgid=22) ⓘ

ALAT↓, 1,   ALP↓, 1,   AST↓, 1,   Bil↓, 1,   CEA↓, 1,  

Functional Outcomes(tgid=23) ⓘ

neuroP↑, 1,   toxicity↝, 1,  
Total Targets: 37

Scientific Paper Hit Count for: DR4, Death Receptor 4
4 Phenethyl isothiocyanate
2 Boswellia (frankincense)
2 Nimbolide
2 Resveratrol
1 Baicalein
1 Ellagic acid
1 Eugenol
1 Fisetin
1 Plumbagin
1 Quercetin
1 Sulforaphane (mainly Broccoli)
1 Thymoquinone
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:806  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid

 

Home Page